Physician profile
Lindsay M Sheets
NPI 1386296838
$4,433.22
in general payments reported to CMS, 2019-2025
26 companies · $673 in 2025
The $673 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $325 · 2023: $1,448 · 2024: $1,987 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,821 · Travel and Lodging: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,821.35 |
| Travel and Lodging | $286.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,054.52 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $656.62 | 2022-2025 | |
| Glaxosmithkline, LLC. | $625.59 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $378.40 | 2023-2025 | |
| Inspire Medical Systems, INC. | $340.18 | 2024 | Inspire |
| Phathom Pharmaceuticals, INC. | $196.28 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $192.98 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $117.34 | 2022-2024 | |
| Novo Nordisk INC | $116.30 | 2022-2025 | Wegovy, Ozempic |
| Amgen INC. | $114.69 | 2023-2025 | Repatha, Otezla, Repatha |
| Idorsia Pharmaceuticals US INC | $82.01 | 2022-2024 | Quviviq |
| Lundbeck LLC | $80.27 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $78.58 | 2023-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.18 | 2022-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $62.53 | 2022-2024 | Trintellix |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $42.21 | 2022 | |
| Merck Sharp & Dohme LLC | $40.76 | 2023-2024 | Dificid, Vaxneuvance, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.37 | 2024-2025 | Jardiance, Ofev |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.23 | 2024 | Caplyta |
| Mylan Specialty L.P. | $25.73 | 2024 | Yupelri |
| Avanir Pharmaceuticals, INC. | $21.09 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.75 | 2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $16.25 | 2023 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $15.23 | 2024 | Injectafer |
| Argenx US, INC. | $14.37 | 2024 | Vyvgart Hytrulo |
| Lilly USA, LLC | $13.76 | 2023 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Sheets listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.